620 filings
Page 6 of 31
8-K
dj5kuayu y6r8
8 May 19
Ublituximab treatment continues to be well tolerated with a median duration of follow-up of 97.5 weeks
12:00am
DEFA14A
e0xon1u3k10
30 Apr 19
Additional proxy soliciting materials
4:35pm
8-K
m53yij1348wg3izv
1 Apr 19
Other Events
8:33am
424B5
fqa42lfo2yi8fto a2t0
5 Mar 19
Prospectus supplement for primary offering
9:01am
8-K
nlnl6kwwyygp
5 Mar 19
Entry into a Material Definitive Agreement
9:00am
424B5
z0hfyf
28 Feb 19
Prospectus supplement for primary offering
4:02pm
8-K
1tetvg xjiar
28 Feb 19
Other Events
7:33am
8-K
gmnws
22 Jan 19
Breakthrough Therapy Designation granted based on interim data from the Marginal Zone Lymphoma cohort of the UNITY-NHL trial
8:07am
8-K
h0iex2x kegv
4 Dec 18
Other Events
7:36am
8-K
5k0adu
9 Nov 18
TG Therapeutics, Inc. Provides Business Update and Reports Third Quarter 2018 Financial Results
7:35am
8-K
h859vy
15 Oct 18
TG Therapeutics, Inc. Announces Final Phase 2 Multiple Sclerosis Data Presentation at the 34th Congress of ECTRIMS
5:20pm
8-K
6b1des 2xveqt5wm
25 Sep 18
TG Therapeutics Announces Update Regarding UNITY-CLL Phase 3 Trial
7:15am
CT ORDER
sams9mag8lrjejggmust
18 Sep 18
Confidential treatment order
12:00am
8-K
8xugj96g
7 Aug 18
Results of Operations and Financial Condition
12:00am
EFFECT
c037xv3 gn
24 Jul 18
Notice of effectiveness
12:15am
CORRESP
hz7rm
18 Jul 18
Correspondence with SEC
12:00am